Assessment of potential treatments for drug-induced respiratory depression and overdose toxicity. POP: september 26, 2022 - march 25, 2023. Task order 75N95022F00001 (TO1).
Ended Awarded Last action
- Contract number
- 75N95022F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $148,800
Award facts
- Opportunity
-
- Assessment of Potential Treatments to Treat Drug-induced Respiratory Depression and Overdose Toxicity Pre-Solicitation · Posted Sep 7, 2021
- Contract value 100% obligated
- $148,800.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $148,800 |
About this award
The National Institutes of Health's National Institute on Drug Abuse awarded a $148,800 cost-plus-fixed-fee delivery order contract to Lovelace Biomedical Research Institute. The task order is being issued against an existing indefinite-delivery/indefinite-quantity contract vehicle to support the assessment of potential treatments for drug-induced respiratory depression and overdose toxicity from September 26, 2022 through September 30, 2024. Lovelace Biomedical will evaluate methods to prevent opioid and other drug overdoses from September 2022 to March 2023 as part of the National Institute on Drug Abuse's efforts to address the public health crisis of opioid abuse and overdose. No subcontractors or set aside designations were identified in the award information.
Quick answers
Who was awarded contract 75N95022F00001?
75N95022F00001 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 26, 2022.
How much is contract 75N95022F00001 worth?
The government has obligated $148,800 on 75N95022F00001.
Is contract 75N95022F00001 an order under another contract?
Yes. 75N95022F00001 is a delivery order under 75N95022D00019, an indefinite delivery contract.
Was contract 75N95022F00001 competed?
The extent of competition for 75N95022F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award